Introduction {#s1}
============

Macrophages are a population of innate myeloid cells that are released from bone marrow as immature monocytic precursors and, after circulating in the blood stream, migrate into different tissues to undergo specific differentiation depending on local cues in the tissue [@pone.0050946-Bingle1], [@pone.0050946-Heusinkveld1]. In response to different environment stimuli, macrophages can appear a range of different phenotypes [@pone.0050946-Siveen1]. The extremes of this range are recognized; the classically activated type M1 phenotype and the alternative activated M2 phenotype. The M1 macrophages are thought to be induced by interferon-γ, with or without lipopolysaccharide, tumor necrosis factor (TNF)-α, and activate cells of the adaptive immune system [@pone.0050946-Mantovani1]. Differentiation of the M2 macrophages is induced by IL-4 or IL-13 and associated with parasite clearance, wound healing and dampen immune responses [@pone.0050946-Biswas1].

In 1863, it was fist found that a major leukocyte population was present in tumor, the so-called tumor-associated macrophages (TAM), which reflect the onset of cancer at site of previous chronic inflammation [@pone.0050946-Bingle1], [@pone.0050946-Virchow1]. These macrophages can induce neoplastic cell (cytotoxicity, apoptosis) and/or elicit tumor destructive reactions with the capacity to display both negative and positive effects on tumor growth depending on environmental stimuli of the tumor tissue [@pone.0050946-Mantovuni1], [@pone.0050946-Mantovuni2].

For long a large number of studies have been focused on identifying the prognostic value of TAM in solid tumors and most studies suggest that TAM is beneficial for tumor growth and, therefore, associated with poor prognosis [@pone.0050946-Bingle1]. However, there are some exceptions with high density of macrophages correlating with increased survival in different tumors [@pone.0050946-Koide1]--[@pone.0050946-Zhou1] and even this contradiction has come up in the one type of tumor [@pone.0050946-Ohno2], [@pone.0050946-Guo1]. This meta-analysis focused on the identifying diverse roles and functions of TAM and subpopulations of TAM for clinical outcome in patients with solid tumors.

Materials and Methods {#s2}
=====================

Identification and Eligibility of Relevant Studies {#s2a}
--------------------------------------------------

We performed our meta-analysis according to a predetermined written protocol. To be eligible for our meta-analysis, studies had to deal with solid tumor at inclusion, to evaluate the correlation between TAM and survival, and to be published in English or Chinese languages. A computer-aided literature search of Pubmed (MEDLINE) 1950-present and EMBASE was conduced by combing search terms "cancer", "tumor", "neoplasm", "carcinoma", "tumor-associated macrophage", "tumor-infiltrating macrophage" and "intratumoral macrophage." The deadline of the included articles was April 20^th^, 2012. Reference list from primary identified studies were also searched to prevent missing any studies by the electronic search strategies.

Inclusion criteria for primary studies were as follows: (1) proven diagnosis of solid tumor in humans, (2) using immunochemistry method to evaluate TAM by anti-CD68, M1-type TAM by anti-HLA-DR and M2-type TAM by anti-CD163, and (3) correlation of TAM with TNM staging, OS or DFS. Two independent reviewers processed primary assessment by identifying the eligibility of abstracts from database. Full articles were retrieved for further assessment if the eligibility was unclear from the abstracts. Any disagreements were resolved by serious discussion. We carefully examined the names of all authors and the medical centers involved in each publication to avoid duplication data. Whenever studies pertained to overlapping patients, we retained the studies with highest number of patients.

Definitions and Standardizations {#s2b}
--------------------------------

We used preconcerted rules to standardize as much as possible the definition of TAM positivity. As 20% was the used as a cutoff value in majority of the included studies [@pone.0050946-Zhou1], [@pone.0050946-Chai1]--[@pone.0050946-Ma1], we defined TAM positivity as positive cell stain in at least 20% of tumor cells. When different definitions were used, we contacted the primary author of each articles to retrieve the cutoff value they used. When cutoff value was not possible to retrieve, we accepted the cutoff was closet to the 20% cutoff level. When cutoff value was closed to 20%, which ranged from 16.3% to 25%, we also accepted the cutoff as 20%.

Data Extraction {#s2c}
---------------

Data were carefully extracted from all of the included studies in duplicate by two of us, using a standard information collection form, with the following items, first author, year of publication, study design, median follow-up time, country of origin, number of patients involved, number of men included, mean or median age, tumor location, histological type, tumor-node-metastasis (TNM) staging, blinded reading, definition of TAM high, anti-cancer treatment(s) during follow up, OS or DFS or both. The main outcomes were tabulated in 2×2 tables showing the TNM staging status, occurrence or not of death or disease during follow-up according to TAM results.

Statistical Analyses {#s2d}
--------------------

Included studies were divided into three groups for analysis: those with data regarding TNM staging, those regarding OS and those regarding DFS. A study was considered significant when the P for comparing survival distribution between groups with high and low TAM was inferior to 0.05. A study was termed "positive" when a high TAM predicted a late clinical staging or poorer survival, "negative" when a high TAM predicted a early clinical staging or better survival, "indeterminate" when no significant relationship between TAM and clinical staging or survival was found.

For the quantitative aggregation of survival result, impacts of TAM on survival were reported for individual studies by estimating RRs with 95% confidence interval values. We first simply extracted RR and their 95%CI from the original article. If not available, the published data including number of patients at risk and total number of events in each groups from articles were used to estimate RR according to the methods described by Parmer et al [@pone.0050946-Parmar1]. When data were only available in the form of figures, we read Kaplan-Meier curves by Engauge Digitizer version 4.1 (free software down-loaded from <http://sourceforge.net>) and extracted survival data to reconstruct RRs and its 95%CI. An observed RR\>1 indicated worse outcome for the TAM high group relative to TAM low group and would be considered statistically significant if the 95%CI did not overlap 1, with p\<0.05. Sensitivity analyses were performed to examine the TAM effect of limiting the evaluation to studies using the 20% cutoff on prognosis. The effect of publication bias on the outcomes was assessed graphically using funnel plots, and funnel plot asymmetry was assessed by Egger\'s linear regression method. (p\<0.05 was considered statistically significant publication bias) [@pone.0050946-Egger1]. Meta-analyses were carried out by the Stata version 11.0 (Stata Corporation, College Station, TX, USA).

Results {#s3}
=======

Studies Selection and Characteristics {#s3a}
-------------------------------------

The initial search algorithm retrieved a total of 3076 references and we evaluated 144 candidate studies in full text. Upon further review, 50 articles were eliminated due to inadequate data for meta-analysis and another 29 articles were out of scope because of evaluating other factors related to TAM ([Figure 1](#pone-0050946-g001){ref-type="fig"}). Overall, we identified 55 articles (n = 8693) with TAM measurements in patients with solid tumors.

![Flow chart of the literature search and selection of included studies.](pone.0050946.g001){#pone-0050946-g001}

The characteristics of included studies are listed in [Table 1](#pone-0050946-t001){ref-type="table"}. The median sample size for all studies was 158 patients (range = 24--1902). The median sample size for staging was 189 patients, that for OS was 164 patients and that for DFS was 202 patients. The total proportion of male subjects was around 45% and that of patients in grade I/II was 43%. All evaluated IHC staining in formalin-fixed paraffin-embedded tissue blocks. The study design was more often a retrospective (N = 25) than a prospective cohort study (N = 5). Only 20% studies had performed blinded reading during evaluating TAM. The median follow-up time for all included studies ranged from 1.84 to 25 years. Of the 55 studies, cut-off value for definition of TAM high only could be retrieved from 32 original articles or by contacting authors.

10.1371/journal.pone.0050946.t001

###### Characteristics of the eligible studies.

![](pone.0050946.t001){#pone-0050946-t001-1}

  First author (ref)                      Year   Study design      n (M/F)      Tumor location    Tumor stage I/II (III/IV)   Median follow-up (y)   Blinded reading   Staining for TAM high                      RR estimation                                     Analysis                                   Result
  -------------------------------------- ------ -------------- --------------- ----------------- --------------------------- ---------------------- ----------------- ----------------------- ----------------------------------------------------- ----------------------------------------- ----------------------------------------
  **Gastrointestinal cancer (N = 19)**                                                                                                                                                                                                                                                        
  Khorana (29)                            2003      Prosp.       131 (69/53)       131 Colon              11 (118)                     5                   NR                  \>2%                     Data extrapolated, Survival curve                           Stag., OS                              Indeterminate
  Tan (12)                                2005      Retro.       60 (35/25)        60 Colon                26 (34)                     NR                  NR                  \>25%                    Data extrapolated, Survival curve                           Stag., OS                                 Negative
  Bacman (30)                             2007        NR        310 (189/121)      310 Colon              178 (132)                   7.5                  NR                   NR                              Data extrapolated                                      OS                                  Indeterminate
  Forssell (15)                           2007      Retro.      488 (271/217)      488 Colon              207 (254)                    NR                  NR                   NR                     Data extrapolated, Reported in text                          Stag., OS                         Indeterminate, negative
  Zhou (18)                               2010        NR         160 (94/66)       160 Colon                 NR                        5                   Yes                  20%                    Data extrapolated, reported in text                          Stag., OS                                 Negative
  Ishigami (31)                           2003      Retro.       97 (72/25)         97 Stom                67 (30)                     NR                  NR               \>200 / HPF                 Data extrapolated, Survival curve                           Stag., OS                         Indeterminate, positive
  Ohno (10)                               2005      Retro.       84 (57/27)         84 Stom                41 (43)                     NR                  Yes                \>4.7%                             Survival curve                                        DFS                                    Negative
  Hass (32)                               2009      Prosp.       52 (40/12)         50 Stom                39 (13)                    5.9                  NR                   NR                              Reported in text                                       DFS                                 Indeterminate
  Kawahara (33)                           2010        NR         111 (77/34)       111 Stom                36 (75)                     NR                  NR                   NR                              Reported in text                                       OS                                     Positive
  Osinsky (34)                            2011      Prosp.       105 (71/34)       105 stom                48 (57)                     NR                  NR                 \>23.0%                           Reported in text                                       OS                                     Positive
  Zhu (22)                                2008      Retro.       105 (96/9)        105 Liver               86 (19)                    1.84                 NR                  \>20%                   Data extrapolated, reported in text                       Stag., OS, DFS                       Indeterminate, positive
  Li (24)                                 2009      Retro.      302 (260/42)       302 Liver              237 (65)                    4.83                 NR                  \>20%                   Data extrapolated, reported in text                       Stag., OS, DFS                       Indeterminate, negative
  Ding (35)                               2009      Retro.       107 (87/20)       107 Liver               98 (39)                    2.5                  MR                  \>23%                            Reported in text                                     OS, DFS                                  Positive
  Kuang (36)                              2009      Retro.        262 (NR)         206 Liver              249 (13)                     NR                  NR                   NR                              Reported in text                                     OS, DFS                                  Positive
  Ju (23)                                 2009      Retro.      130 (112/18)       130 Liver               66 (64)                    2.65                 NR                  \>20%                            Reported in text                                 Stag., OS, DFS                               Positive
  Koide (9)                               2002      Retro.       56 (42/14)      56 Esophagus              30 (26)                     NR                  NR                   NR                      Data extrapolated, survival cure                            Stag., OS                         Indeterminate, negative
  Guo (19)                                2007        NR        137 (103/34)     137 Esophagus             86 (51)                     NR                  NR                  \>25%                            Reported in text                                    Stag., OS                         Indeterminate, positive
  Kurahara (37)                           2012      Retro.       76 (52/24)       52 Pancreas              29 (47)                     NR                  Yes                  NR                               Survival curve                                     OS, OS^b^                              Indeterminate
  Hasita (38)                             2010        NR         39 (27/12)      55 Bile duct              29 (10)                    3.33                 Yes                  NR                      Data extrapolated, survival curve            Stag., OS, DFS, Stag.^b^, OS^b^, DFS^b^               Indeterminate
  **Urogenital cancer (N = 20)**                                                                                                                                                                                                                                                              
  Leek (39)                               1996      Retro.       101 (0/101)       5 Breast                  NR                        NR                  NR               MD \> = 12                          Reported in text                                     OS, DFS                                  Positive
  Toi (40)                                1999        NR         229 (0/229)      229 Breast                 NR                        4                   Yes                  NR                               Survival curve                                        DFS                                 Indeterminate
  Valkovic (41)                           2002        NR          97 (0/97)        97 Breast               82 (15)                     NR                  NR                   NR                              Data extrapolated                                     Stag.                                Indeterminate
  Bolat (42)                              2006      Retro.        78 (0/78)        78 Breast               38 (10)                     NR                  NR                   NR                              Data extrapolated                                     Stag.                                Indeterminate
  Mahmound (43)                           2012      Retro.      1902 (0/1902)     1902 Breast            220 (1682)                    NR                  NR                   NR                      Data extrapolated, survival curve                          Stag., DFS                         Positive, indeterminate
  Salvesen (44)                           1999      Prosp.        60 (0/60)     60 Endometrium             50(10)                      11                  NR                   NR                     Data extrapolated, reported in text                          Stag., OS                         Positive, indeterminate
  Hashimoto (45)                          2000        NR         109 (0/109)    109 Endometrium            56(53)                     4.58                 NR                   NR                              Data extrapolated                                  Stag., DFS                              Indeterminate
  Ohno (11)                               2004      Retro.        70 (0/70)     70 Endometrium               NR                        NR                  NR                MD \>10.7                           Survival curve                                        DFS                                    Negative
  Soeda (46)                              2008      Retro.        76 (0/76)     76 Endometrium             59(17)                     6.83                 NR                   NR                               Survival curve                                      OS, DFS                          Positive, indeterminate
  Espinosa (47)                           2010        NR          64 (0/64)     64 Endometrium             23(26)                      NR                  NR                   NR                              Data extrapolated                                   Stag.^b^                               Indeterminate
  Lissbrant (48)                          2000      Retro.        85 (85/0)       85 Prostate              75(10)                      NR                  NR               \> = 0.97%                           Survival curve                                     Stag., OS                              Indeterminate
  Shimura (49)                            2000        NR          81 (81/0)       81 Prostate              67(13)                     3.9                  NR                   NR                              Reported in text                                       DFS                                 Indeterminate
  Nonomura (50)                           2011        NR         131 (131/0)     131 Prostate              30(41)                     2.9                  NR               MD \> = 22                           Survival curve                                        DFS                                    Positive
  Heller (51)                             2002      Retro.        24 (0/24)        24 Cervix                20/4                       NR                  NR                   NR                              Data extrapolated                                     Stag.                                Indeterminate
  Kawanaka (52)                           2008      Retro         73 (0/73)        73 Cervix                22/51                      NR                  Yes              MD \> = 55                           Survival curve                                        DFS                                 Indeterminate
  Hanada (53)                             2000        NR         63 (51/12)       63 Bladder                42/21                     5.4                  Yes              MD \> = 67                 Data extrapolated, reported in text                          Stag., OS                                 Positive
  Takayama (54)                           2009        NR          41 (38/3)       41 Bladder                 NR                        25                  NR                 \> = 4                            Reported in text                                       DFS                                    Positive
  Tanaka (55)                             2004        NR          89 (0/89)        89 Ovary                 22/67                     6.8                  NR                \> = 25%          Data extrapolated, reported in text, survival curve               Stag., OS, DFS                  Negative, positive, indeterminate
  Wan (25)                                2009        NR          67 (0/67)        67 Ovary                 0/67                       NR                  NR                  \>20%                             Survival curve                                        OS                                     Positive
  Chai (20)                               2008        NR         99 (42/57)        99 Uroth                  NR                        NR                  NR                  \>20%                            Reported in text                                     OS, DFS                          Indeterminate, positive
  **Lung cancer (N = 10)**                                                                                                                                                                                                                                                                    
  Takanami (56)                           1999      Retro.       113 (66/47)       113 Lung                 61/52                      NR                  NR                 MD\>32                             Survival curve                                        OS                                     Positive
  Chen (57)                               2005        NR         41 (27/14)         41 Lung                 23/18                      NR                  NR               MD\> = 163                           Survival curve                                        DFS                                 Indeterminate
  Welsh (13)                              2005      Retro.      175 (116/59)       175 Lung                123/38                      NR                  Yes                  NR                              Data extrapolated                                  Stag., DFS                                 Negative
  Zeni (58)                               2007        NR          50 (43/7)         43 Lung                  NR                        NR                  NR                 \>16.3%                   Reported in text, survival curve                            Stag., OS                                 Positive
  Kawai (16)                              2008        NR        199 (139/60)       199 Lung                  NR                        NR                  NR                   NR                              Reported in text                                       OS                                     Negative
  Ohri (17)                               2009      Retro.       40 (16/24)         40 Lung                 34/6                       NR                  NR                   NR                               Survival curve                                        OS                                     Negative
  Al-shibli (59)                          2009      Retro.      371 (253/82)       371 Lung                303/32                      8                   NR                \> = 25%                   Data extrapolated, survival curve                            OS, DFS                               Indeterminate
  Ma (26)                                 2010        NR         50 (40/10)         50 Lung                 33/17                      NR                  NR                  \>20%                            Reported in text                                  OS^a^, OS^b^                             Indeterminate
  Ohtaki (60)                             2010      Prosp.       170 (85/85)       170 Lung                  NR                       10.1                 NR                   NR                              Data extrapolated                                   Stag., OS                                 Positive
  Zhang (61)                              2011      Retro.       65 (38/27)         65 Lung                 38/27                      NR                  Yes           TAM counts \>102                        Survival curve                                        OS                                     Positive
  **Head and neck cancer (N = 4)**                                                                                                                                                                                                                                                            
  Liu (21)                                2008        NR         112 (93/19)       112 Oral                 50/62                      NR                  NR                  \>20%                    Data extrapolated, survival curve                           Stag., OS                                 Positive
  Fujii (62)                              2012        NR         108 (31/10)       108 Oral                 46/62                      NR                  NR               \> = 2/HPF                 Data extrapolated, reported in text                   Stag., stag.^b^, OS^b^              Positive, indeterminate, positive
  Peng (14)                               2006        NR         60 (38/22)         60 Oral                 15/45                      NR                  NR              \> = 63.7/HPF                        Data extrapolated                                      OS                                     Negative
  Lin (63)                                2011        NR          84 (77/7)         84 Lar                  30/54                      NR                  NR               \> = 10/HPF                Data extrapolated, reported in text                       Stag., OS, DFS                Indeterminate, indeterminate, positive
  **Thyroid cancer (N = 1)**                                                                                                                                                                                                                                                                  
  Ryder (64)                              2008        NR         37 (13/24)         37 Thyr                 5/32                       NR                  Yes              \> = 10/HPF                          Survival curve                                        OS                                     Positive
  **Mesothelioma (N = 1)**                                                                                                                                                                                                                                                                    
  Burt (65)                               2011      Retro.      667 (531/136)      667 Meso                64/603                      NR                  Yes                  NR                              Reported in text                                       OS                                  Indeterminate

Of the included studies, 19 studies focused on gastrointestinal cancers, including colorectal cancer (N = 5), gastric cancer (N = 5), liver cancer (N = 5), esophagus cancer (N = 2), pancreatic caner (N = 1) and cholangiocarcinoma (N = 1). 20 studies analyzed the impact of TAM on survival in patients with urogenital cancers, including breast cancer (N = 5), endometrial cancer (N = 5), prostate cancer (N = 3), cervical cancer (N = 2), bladder cancer (N = 2), ovary cancer (N = 2) and urothelial cancer (N = 1). 5 studies mentioned the value of M2-type TAM on survival [@pone.0050946-Ma1], [@pone.0050946-Kurahara1], [@pone.0050946-Hasita1], [@pone.0050946-Espinosa1], [@pone.0050946-Fujii1].

Data Synthesis: Clinical Staging {#s3b}
--------------------------------

As shown in [Figure 2A](#pone-0050946-g002){ref-type="fig"}, the combining data of TAM on clinical staging showed a nonstatistically significant RR of 1.13 (95%CI 0.97--1.31). For sub-group analysis, all of the studies were dispatched into several classes according to the tumor location. Our data showed that high density of TAM was significantly higher in patients with advanced tumor stage (III+IV) than in the patients with early stage (I+II), which occurred in breast cancer \[RR = 1.20 (95%CI, 1.14--1.28)\], oral cancer \[RR = 1.49 (95%CI, 1.17--1.89)\] and bladder cancer \[RR = 3.30 (95%CI, 1.78--7.92)\],whereas 1 article focused on ovary cancer found high density of TAM was associated with early stage \[RR = 0.52 (95%CI, 0.36--0.77)\]. Other sub-group analysis found no relation between TAM and clinical staging. In studies specific defining TAM positivity as at least 20% positive staining cells in tumor tissue, no significant relation was found between TAM and clinical staging (RR = 1.23 (95%CI, 0.74--2.02). Analysis for M2-type TAM on staging also showed no significant effect \[RR = 1.43 (95%CI, 0.70--2.93)\].

![Forrest plots and meta-analysis of studies evaluating RR of high TAM counts as compared to low counts.\
Clinical staging and survival data are reported as (**A**) staging, (**B**) overall survival (OS) and (**C**) disease free survival (DFS).](pone.0050946.g002){#pone-0050946-g002}

Data Synthesis: Overall Survival {#s3c}
--------------------------------

For overall population, high density of TAM was associated with a worse prognosis regarding overall survival ([Figure 2B](#pone-0050946-g002){ref-type="fig"}). However, mortality was only 1.15-fold higher in high TAM patients with solid tumor, which showed modest effect. In sub-group analysis ([Figure 3](#pone-0050946-g003){ref-type="fig"}), high density of TAM was significantly correlated with poor OS in patients with urogenital cancer \[RR = 1.95 (95%CI, 1.32--2.86)\], including breast cancer \[RR = 8.62 (95%CI, 3.10--23.95)\], endometrial cancer \[RR = 1.85 (95%CI, 0.10--34.63)\], prostate cancer \[RR = 1.16 (95%CI, 0.96--1.40)\], bladder cancer \[RR = 5.00 (95%CI, 1.98--12.63)\], ovary cancer \[RR = 2.55 (95%CI, 1.60--4.06)\] and urothelial cancer \[RR = 1.01 (95%CI, 1.32--2.86)\]. In addition, gastric cancer and oral cancer showed significant RR between TAM and OS \[RR = 1.54 (95%CI 1.24--2.16), 2.03 (95%CI 1.47--2.80)\]. However, analysis of studies on colorectal cancer showed that there was a significant correlation between high density of TAM and longer OS \[RR = 0.64 (95%CI, 0.43--0.96)\]. No significant correlation between TAM and OS was found in other sub-group analysis. Five studies reported that there was no significant correlation between M2-type TAM and OS \[RR = 0.98 (95%CI, 0.71--1.35)\], one study reported that the M1-type TAM density in the tumor islet is positively associated with extended survival in patients with lung cancer [@pone.0050946-Ohri1]. There was also no difference in the summary estimate of TAM on overall survival when cutoff value was specific to 20% (RR = 1.41 (95%CI, 1.03--2.09).

![Forrest plots and meta-analysis of studies evaluating RR of high TAM counts as compared to low counts in different subgroup of tumors.\
Clinical staging and survival data are reported as (**A**) gastrointestinal cancer, (**B**) urogenital cancer, (**C**) lung cancer and (**D**) head and neck cancer.](pone.0050946.g003){#pone-0050946-g003}

Data Synthesis: Disease free survival {#s3d}
-------------------------------------

For the overall population, no significant relation was observed between TAM and DFS \[RR = 1.01 (95%CI, 0.99--1.04)\]([Figure 2C](#pone-0050946-g002){ref-type="fig"}). No significant effect was showed in sub-group analysis. One article [@pone.0050946-Hasita1] with data on M2-type TAM and DFS also showed a non-significant effect \[RR = 1.09 (95%CI, 0.77--1.54)\]. Analysis for specific 20% cutoff also showed no significant effect (RR = 1.19 (95%CI, 0.78--1.57).

Data Synthesis in sub-groups: clinic-pathological factors {#s3e}
---------------------------------------------------------

The impact of TAM density on clinic-pathological in patients with different cancer was further analyzed and described in [Table 2](#pone-0050946-t002){ref-type="table"}. Two studies [@pone.0050946-Tan1], [@pone.0050946-Khorana1] showed a significant correlation between T status and TAM density, nevertheless, no correlation was found between TAM density and lymph node metastasis nor distant metastasis. High density of TAM was also correlated with nonmucinous type of colon cancer. Additionally, two of the studies on gastric cancer described that low density of TAM was significantly correlated with lymph node metastasis [@pone.0050946-Ishigami1], [@pone.0050946-Haas1]. In the breast cancer group, Negative effects of TAM were found not only on TNM stage, but also histological grade, lymph node metastasis, tumor size, vascular invasion and HER-2 status. Similar phenomena were seen in bladder cancer and oral squamous group, and high density of TAM was significantly correlated with TNM stage, T status, lymph node metastasis and distant metastasis. In addition, one study demonstrated that the density of TAM was significantly lower in patients with advanced tumor stage (III/IV) than in patients with early stage (I/II) [@pone.0050946-Tanaka1].

10.1371/journal.pone.0050946.t002

###### Meta-analysis of the subgroups based on clinic-pathological factors related to TAM density from the available published studies.

![](pone.0050946.t002){#pone-0050946-t002-2}

  Cancer type                                            Clinic-pathological factors                    Number of studies   Number of total patients      HR (95% CI)       *p*-value      Results         Reference
  ------------------------------------- -------------------------------------------------------------- ------------------- -------------------------- -------------------- ----------- --------------- ------------------
  **Colon cancer**                                                                                                                                                                                     
                                                         TNM Stage (I/II vs. III/IV)                            2                     619              0.71 (0.35, 1.45)      0.194     Indeterminate      (15), (29)
                                                          T status (T1/T2 vs. T3/T4)                            2                     191              0.35 (0.13, 0.90)      0.246       Positive         (12), (29)
                                                            Lymph node metastasis                               2                     370              0.72 (0.13, 4.06)      0.013     Indeterminate      (12), (30)
                                                              Distant metastasis                                3                     530              0.72 (0.24, 2.11)      0.005     Indeterminate   (12), (18), (30)
                                                 Histological grade (well/moderate vs. poor)                    3                     858              0.26 (0.06, 1.06)      0.005     Indeterminate   (12), (15), (30)
                                             Pathologic classification (mucinous vs. nonmucinous)               2                     648              2.53 (1.35, 4.73)      0.675       Negative         (15), (18)
  **Gastric cancer**                                                                                                                                                                                   
                                                         TNM Stage (I/II vs. III/IV)                            1                      97              2.40 (0.98, 5.91)       NR       Indeterminate        \(31\)
                                                          T status (T1/T2 vs. T3/T4)                            1                      97              1.36 (0.54, 3.46)       NR       Indeterminate        \(31\)
                                                            Lymph node metastasis                               2                     149              0.39 (0.19, 0.80)      0.302       Positive         (31), (32)
                                                              Distant metastasis                                1                      52              1.30 (0.40, 4.28)       NR       Indeterminate        \(32\)
                                                 Histological grade (well/moderate vs. poor)                    1                      97              0.54 (0.22, 1.32)       NR       Indeterminate        \(31\)
  **Liver cancer**                                                                                                                                                                                     
                                                         TNM Stage (I/II vs. III/IV)                            3                     514              1.27 (0.84, 1.93)      0.702     Indeterminate   (22), (24), (35)
                                                    Vascular invasion (absent vs. present)                      3                     514              1.38 (0.87, 2.21)      0.410     Indeterminate   (22), (24), (35)
                                                            Tumor differentiation                               2                     409              1.08 (0.70, 1.66)      0.956     Indeterminate      (24), (35)
                                                          Tumor size (≤5 vs. \>5cm)                             2                     409              1.76 (1.19, 2.60)      0.329       Negative         (24), (35)
                                                        Hepatitis history (No vs. Yes)                          2                     407              1.45 (0.80, 2.60)      0.456     Indeterminate      (22), (24)
                                                         Liver cirrhosis (No vs. Yes)                           3                     514              1.18 (0.75, 1.88)      0.886     Indeterminate   (22), (24), (35)
                                                     Fibrous capsule (absent vs. present)                       3                     514              0.83 (0.58, 1.19)      0.750     Indeterminate   (22), (24), (35)
  **Esophagus cancer**                                                                                                                                                                                 
                                                          T status (T1/T2 vs. T3/T4)                            1                      56              2.73 (0.70, 10.60)      NR       Indeterminate        \(9\)
                                                            Lymph node metastasis                               1                      56              0.75 (0.21, 2.59)       NR       Indeterminate        \(9\)
                                                   Lymphatic invasion (absent vs. present)                      1                      56              3.21 (0.81, 12.8)       NR       Indeterminate        \(9\)
                                                     Venous invasion (absent vs. present)                       1                      56              6.22 (1.48, 26.1)       NR         Negative           \(9\)
  **Intrahepatic cholangiocarcinoma**                                                                                                                                                                  
                                                         UICC stage (I/II vs. III/IV)                           1                      55              3.31 (0.71, 15.4)       NR       Indeterminate        \(38\)
                                                 Histological grade (well/moderate vs. poor)                    1                      55              5.25 (0.93, 29.7)       NR       Indeterminate        \(38\)
                                                            Lymph node metastasis                               1                      55              1.06 (0.19, 6.05)       NR       Indeterminate        \(38\)
                                                    Vascular invasion (absent vs. present)                      1                      55              2.13 (0.34, 13.2)       NR       Indeterminate        \(38\)
                                                          Tumor size (\<4 vs. ≥4cm)                             1                      55              1.38 (0.39, 4.87)       NR       Indeterminate        \(38\)
  **Breast cancer**                                                                                                                                                                                    
                                                         TNM Stage (I/II vs. III/IV)                            1                      78              1.20 (1.14, 1.28)       NR         Negative           \(42\)
                                                      Histological grade (I/II vs. III)                         3                     2077             3.42 (2.71, 4.30)      0.742       Negative      (41), (42), (43)
                                                            Lymph node metastasis                               3                     2077             1.29 (1.04, 1.62)      0.604       Negative      (41), (42), (43)
                                                          Tumor size (≤2 vs. \>2cm)                             3                     2077             1.43 (1.14, 1.80)      0.963       Negative      (41), (42), (43)
                                                    Vascular invasion (absent vs. present)                      1                     1902             1.74 (1.35, 2.23)       NR         Negative           \(43\)
                                                     HER-2 status (negative vs. positive)                       1                     1902             2.59 (1.75, 3.85)       NR         Negative           \(43\)
  **Endometrial cancer**                                                                                                                                                                               
                                                         FIGO stage (I/II vs. III/IV)                           2                     169              2.34 (0.36, 15.39)     0.021     Indeterminate      (44), (45)
                                                            Lymph node metastasis                               1                     109              0.43 (0.12, 1.53)       NR       Indeterminate        \(45\)
                                                 Myometrial invasion (negative vs. positive)                    1                     109              2.09 (0.65, 6.69)       NR       Indeterminate        \(45\)
                                                      Histological grade (I/II vs. III)                         2                     169              4.34 (0.70, 27.08)     0.044     Indeterminate      (44), (45)
                                         Pathologic classification (Endometrioid vs.non-endometrioid)           1                     109              1.37 (0.41, 4.62)       NR       Indeterminate        \(45\)
  **Prostate cancer**                                                                                                                                                                                  
                                                          T status (T1/T2 vs. T3/T4)                            1                      85              3.30 (1.56, 6.96)       NR       Indeterminate        \(48\)
                                                              Distant metastasis                                1                      85              1.06 (0.25, 4.54)       NR       Indeterminate        \(48\)
  **Cervical cancer**                                                                                                                                                                                  
                                                         FIGO stage (I/II vs. III/IV)                           2                      97              0.68 (0.06, 8.26)      0.063     Indeterminate      (51), (52)
                                                            Lymph node metastasis                               1                      24              1.75 (0.26, 11.7)       NR       Indeterminate        \(51\)
  **Bladder cancer**                                                                                                                                                                                   
                                                         TNM Stage (I/II vs. III/IV)                            1                      63              5.76 (1.76, 18.9)       NR         Negative           \(53\)
                                                          T status (T1/T2 vs. T3/T4)                            1                      63              17.6 (4,34, 71.1)       NR         Negative           \(53\)
                                                              Distant metastasis                                1                      63              12.4 (2.50, 61.0)       NR         Negative           \(53\)
                                                    Vascular invasion (absent vs. present)                      1                      63              10.8 (1.26, 92.4)       NR         Negative           \(53\)
  **Ovary cancer**                                                                                                                                                                                     
                                                         TNM Stage (I/II vs. III/IV)                            1                      89              0.52 (0.35, 0.77)       NR         Positive           \(54\)
                                                            Lymph node metastasis                               1                      89              0.14 (0.05, 0.35)       NR         Positive           \(54\)
                                                            Tumor differentiation                               1                      89              0.79 (0.34, 1.83)       NR       Indeterminate        \(54\)
                                                          Tumor size (≤5 vs. \>5cm)                             1                      89              0.94 (0.41, 2.17)       NR       Indeterminate        \(54\)
                                                   Histological type (serous vs. nonserous)                     1                      89               0.81 (0.34, 1.9)       NR       Indeterminate        \(54\)
  **Lung cancer**                                                                                                                                                                                      
                                                      Pathologic stage (I vs. II/III/IV                         2                     345              1.29 (0.24, 6.78)     \<0.001    Indeterminate      (13), (60)
                                                            Tumor differentiation                               1                     170              5.80 (2.99, 11.2)       NR         Negative           \(60\)
                                                          T status (T1/T2 vs. T3/T4)                            1                     170              2.70 (1.40, 5.21)       NR         Negative           \(60\)
                                                            Lymph node metastasis                               1                     170              2.72 (1.27, 5.82)       NR         Negative           \(60\)
                                                               Vessel invasion                                  1                     170              3.24 (1.69, 6.24)       NR         Negative           \(60\)
  **Oral squamous cell carcinoma**                                                                                                                                                                     
                                                         TNM Stage (I/II vs. III/IV)                            2                     220              2.53 (1.46, 4.38)      0.888       Negative         (21), (62)
                                                          T status (T1/T2 vs. T3/T4)                            2                     220              2.33 (1.34, 4.03)      0.328       Negative         (21), (62)
                                                            Lymph node metastasis                               2                     220              2.56 (1.46, 4.47)      0.528       Negative         (21), (62)
                                                            Tumor differentiation                               2                     220              1.32 (0.68, 2.57)      0.294     Indeterminate      (21), (62)
  **Thyroid cancer**                                                                                                                                                                                   
                                                         TNM Stage (I/II vs. III/IV)                            1                      37              4.31 (0.42, 43.7)       NR       Indeterminate        \(64\)
                                                              Distant metastasis                                1                      37              4.17 (0.66, 26.1)       NR       Indeterminate        \(64\)

Evaluation of publication bias {#s3f}
------------------------------

Both Begg\'s funnel plot and Egger\'s test were performed to assess the publication bias in all studies evaluating staging, OS, DFS separately, and evaluation was also performed in sub-group analysis. Begg\'s funnel plot did not reveal any evidence of significant asymmetry in the overall meta-analysis of staging (p = 0.679), OS (p = 0.065) and DFS (p = 0.792)([Figure 4](#pone-0050946-g004){ref-type="fig"}). There was also no indication of publication in Egger\'s test of staging (p = 0.993), OS (p = 0.058) and DFS (p = 0.357). For sub-group evaluation of publication bias, no significant publication bias was shown from either Egger\'s or Begg\'s test (not shown).

![Funnel graph for assessment of potential publication bias in studies of TAM density in patients with solid tumor.\
(**A**) Staging, (**B**) OS, (**C**) DFS. The funnel graph plots log HR against the standard error of the log HR. The result of the Egger\'s test showed no statistical significant (p\>0.05).](pone.0050946.g004){#pone-0050946-g004}

Discussion {#s4}
==========

So far, a group of original articles and reviews has studied the prognostic significance of TAM in solid tumors, and the presence of both significant and non-significant studies addressing the importance of TAM on survival made it necessary to perform a quantitative aggregation of the survival results. The present result showed that high density of TAM, as detected with immunohistochemistry, was significant associated with worse overall survival in solid tumor, with a global RR of 1.15. As potential bias exists between studies on different tumors, subgroup analysis was also performed, which suggested that high density of TAM was significant associated with OS in patients with gastric cancer \[RR = 1.64 (95%CI, 1.24--2.16)\], breast cancer \[RR = 8.62 (95%CI, 3.10--23.95)\], bladder caner \[RR = 5.00 (95%CI, 1.98--12.63)\], ovarian cancer \[RR = 2.55 (95%CI, 1.60--4.06)\], oral cancer \[RR = 2.03 (95%CI, 1.47--2.80)\] and thyroid cancer \[RR = 2.72 (95%CI, 1.26--5.86)\]. Moreover, there showed positive effect in patients with colorectal cancer \[RR = 0.64 (95%CI, 0.43--0.96)\]. However, no significant effect was seen between TAM and DFS.

When comparing the results of different types of tumors, several key differences were observed. As mentioned above, although macrophages under certain conditions can kill tumor cells, they can also play potential roles as tumor promoters to secrete a variety of factors that directly stimulate tumor invasion and metastasis. The combing effect of TAM on prognosis in patients with different tumors depends on stimulating factors from two opposite aspects in tumor environments. In this meta-analysis, we reach a conclusion that high TAM infiltration is associated with worsen prognosis in patients with urogenital cancer or gastric cancer, not all cancer type. In other hand, TAM showed antitumorigenic properties in combing 5 studies on colorectal cancer, resulting in improved prognosis.

To further investigate the prognostic value of TAM in different type of cancer, we analyzed the relation between the density of TAM and clinic-pathological factors that was also associated with outcome of cancer patients. As the density of TAM has a negative effect on survival in patients with gastric cancer, breast cancer, bladder cancer, ovary cancer, and oral squamous cell carcinoma, negative effects are also seen in clinic-pathological factors such as TNM staging (breast cancer, bladder cancer and oral squamous cell carcinoma), T status (breast cancer and oral squamous cell carcinoma), lymph node metastasis (breast cancer, bladder cancer and oral squamous cell carcinoma), and distant metastasis (bladder cancer), which contributed to tumor progression and patient survival. Interestingly, there also demonstrated a positive effect of TAM on lymph node metastasis in gastric and ovary cancer, which indicated that high density of TAM was associated with less probability of lymph node metastasis, however, significant negative effect was shown on overall survival. Thus, more studies are needed to clarify this ambivalent phenomenon. Contrary to tumors we mentioned above, our data suggested that an incremental increase in density of TAM improved overall survival in patients with colon cancer, with a homodromous effect on T status. There was also a trend towards lower rate of lymph node metastasis and distant metastasis in TAM rich tumors. In addition, a high density of TAM infiltration was found related to nonmucious type of colon cancer.

The mechanisms behind the oncogenic and anti-tumorigenic effects of TAMs have not been fully elucidated and a great number of studies have focused on explaining these apparently contradictory effects of TAM in different cancer outcome. The functions of TAM in different type of tumors are concerned as the most important determining factor to the prognosis, which are profoundly affected by microenvironmental signals and can range from powerful stimulation of inflammatory responses to induction of immunosuppression [@pone.0050946-Gordon1]. Tumor necrosis factor (TNF)-α, nitric oxide (NO), and monocyte chemoattractant protein (MCP)-1 released from TAM are major intermediate molecules for tumor cell killing [@pone.0050946-Xie1]--[@pone.0050946-Nesbit1], and TAM associated vascular endothelial growth factor (VEGF) and matrix metalloproteinases (MMPs) are independent predictor of poor prognostic factor in cancer patients [@pone.0050946-Osinsky1]. In addition, a macrophage balance hypothesis between M1 and M2 type macrophages has been proposed and two different macrophage populations range from polarized potent killer M1 cells to alternatively activated M2 macrophages with tumor-promoting capability [@pone.0050946-Umemura1]. However, this study showed no significant relation between the density of two phenotype of TAM and survival of patients. Furthermore, histological classification of the tumor should also be considered as a factor correlated with the function of TAM. A previous study on colon cancer demonstrated that a histologically more malignant phenotype was associated with macrophage infiltration, disorganized matrix deposition, and extensive stromal reaction [@pone.0050946-Oosterling1]. In one included study of this meta-analysis, the number of infiltrating TAM was found to be significantly correlated with poor outcome in patients with intestinal type of gastric cancer, but not in patients with diffuse type, indicating that TAM could affect malignant progression and prognosis on the basis of the histological type of gastric cancer [@pone.0050946-Kawahara1].

Although the results of meta-analysis are considered as gold standards by authors worldwide [@pone.0050946-Stewart1], potential bias still exists between studies and cannot be completely eliminated. Although Begg\'s funnel plot and Egger\'s test were performed in this meta-analysis and found no statistically significant publication bias, results of this study should be interpreted very cautiously and several aspects of importance in this field should be discussed. First of all, we only included studies from which we could extract RR or estimate RR, leading to data inaccessible for data aggregation from studies, which only showed the conclusion on this topic without data presented. Take one excluded study on evaluating the prognostic value of TAM on oral cavity and oropharyngeal squamous cell carcinoma for example, they found that macrophage content was an independent predictor of lymph node metastasis, however, no data was accessible for meta-analysis from this study [@pone.0050946-Marcus1]. Furthermore, considerable attention should be paid to some cancers with few study included in this meta-analysis study. TAM was found associated with worse prognosis in one study on oral cancer \[RR = 2.03 (95%CI, 1.47--2.80)\] [@pone.0050946-Liu1] and one study on thyroid cancer \[RR = 2.72 (95%CI, 1.26--5.86)\] [@pone.0050946-Ryder1]. As meta-analysis could not be performed with such small number of primary studies, more researches are needed in further investigation on these tumors.

Second, macrophages can be identified by cell surface markers, expression of transcriptional factors, the production of cytokines and their functions in vitro [@pone.0050946-Heusinkveld1]. However, we only included literatures evaluating TAM with the use of antibodies to the glycoprotein CD68. Sikert et al quantified TAM by immunohistochemistry with antibodies to PG-M1, KP-1, MRP8, MRP14 and MRP8/14 antigens and found different TAM subpopulation were positively correlated with clinicopathological characteristics in colon cancer [@pone.0050946-Sickert1]. Macrophage differentiation, growth, and chemotaxis are regulated by several growth factors, including colony-stimulating factor (CSF)-1, macrophage chemoattractant protein (MCP)-1 and extracellular matrix protease such as urokinase-type plasminogen activator (uPA) [@pone.0050946-Liguori1]. For example, over expression of CSF is associated with poor prognosis in nongynecological leiomyosarcoma [@pone.0050946-Espinosa2]. In breast cancer, TAM density is showed correlated with angiogenesis and poor prognosis [@pone.0050946-Valkovic2]--[@pone.0050946-Fujimoto1]. Ohba et al provide the evidence that uPA has prognostic value in patients with renal cell carcinoma via TAM [@pone.0050946-Ohba1]. Also other factors could be used to evaluate M1 and M2 type macrophages in tumor tissues. As M2 type TAM express high level of interleukin-10 (IL-10) which can be used to discriminate between M1 and M2 macrophages [@pone.0050946-AvilaMoreno1], [@pone.0050946-Verreck1], a study assessed IL-10 expression in TAM, and found the high level of IL-10 in TAM significantly correlated with clinical staging and histologic poor differentiation in patients with lung cancer [@pone.0050946-Wang1]. So, considerable attention should be paid to various kinds of factors related to density of TAM, which might be a potential prognostic marker in solid tumor.

Third, variability in definitions, outcomes, measurements, experimental procedure, and even antibody concentration may contribute to heterogeneity between studies [@pone.0050946-Simon1]. Multivariate analyses was tried to minimize confounding bias, but the factors controlled for were few and differed between studies. Quality criteria are needed for future studies in this field, and we make the following recommendation: blindly assess the prognostic marker to patient outcome, adequately describe the assay method used for TAM evaluation including antibody concentration and cut-off value staining for TAM high, and precisely define outcome with certain follow-up time. More importantly, in this meta-analysis, some studies have used 20% as the cutoff value, whereas others have chosen score system, mean, median or arbitrary cutoff values, thus cutoff value is a source of considerable interstudy heterogeneity. Although specific synthesis of studies using standardized cutoff value on survival did not differ significantly form the overall result in the total population analysis, conclusions need to be considered cautiously.

In conclusion, it is clear that TAM has protumorigenic as well as antitumorigenic properties in solid tumor. As discussed above, there have been showed a "macrophage balance" on prognosis depending on the microenvironment of the tumor tissue in different type of solid tumor. It may be possible in the future to use or induce activated macrophages to restrain tumor growth and improve patient survival, through altering tumor microenvironment. Moreover, targeted therapies that uniquely strike macrophages may provide innovative therapeutic strategies against tumor progression.
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